Overview

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
Therapeutics, Inc.